NCT04018365View on ClinicalTrials.gov

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

PHASE3UnknownINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

October 30, 2021

Conditions
Insulin Resistance - Type AInsulin Resistance - Type BLipoatrophic Diabetes MellitusInsulin Resistance Syndrome
Interventions
DRUG

Empagliflozin Tablets

The administration is oral administration with water before or after breakfast.

Trial Locations (5)

650-0017

Kobe University Hospital, Kobe

980-8574

Tohoku University Hospital, Sendai

329-0498

Jichi Medical University Hospital, Shimotsuke

101-8309

NIhon University Hospital, Chiyoda-ku

700-8558

Okayama University Hospital, Okayama

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Kobe University

INDUSTRY